Beneficial But also Attractive ISRIB Guidelines

Of 3,283 patients with valid PRU measurements, 625 (19.0%) met the inclusion criterion of PRU >208 and were invited to participate in the randomized study. A total of 202 patients declined participation in the study. We, thus, finally randomized 423 patients, 212 of whom were assigned to prasugrel and 211 to clopidogrel. click here Within each group, 210 patients received at least 1 dose of the assigned study medication. There were no significant differences in any of the baseline, clinical, and procedural characteristics between the 2 treatment arms (Table 1). Baseline PRU was well matched between the 2 study groups (p = 0.805) (Table 1, Fig. 2). One hundred forty-seven patients discontinued the study prematurely after a median of 90 days (interquartile range: 44 to 132 days). This was mostly due to early termination of the study (n = 118); other reasons included early revocation of consent (n = 5) or unwillingness to continue with the study (n = 24). Finally, 136 patients assigned to prasugrel and 137 patients assigned to clopidogrel ultimately completed the study. In the prasugrel arm, we obtained a least 1 valid PRU measurement on study medication in 191 patients and a valid subsequent PRU measurement in 139 patients on the study drug. In the clopidogrel arm, the respective numbers were 197 and 144. At the first blinded CYTH4 PRU measurement in patients on the study drug, which was performed after a median of ISRIB in vivo 90 days (interquartile range: 88 to 94 days), median PRU on prasugrel was significantly lower than that on clopidogrel (Fig. 2). Thus, we observed a substantial decrease in PRU in the prasugrel arm (p